Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 03, 2019 16:45 ET | Source: MeiraGTx

MeiraGTx to Present at Upcoming Scientific and Investor Conferences

LONDON and NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the Company will...
September 10, 2019 08:30 ET | Source: MeiraGTx

MeiraGTx To Present Clinical Data from Phase 1/2 Trial of AAV-RPE65 at Upcoming Scientific Conferences

LONDON and NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that clinical data updates...
August 08, 2019 06:50 ET | Source: MeiraGTx

MeiraGTx Announces Pricing of Public Offering of Ordinary Shares

LONDON and NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the pricing of an...
August 07, 2019 16:12 ET | Source: MeiraGTx

MeiraGTx Announces Proposed Public Offering of Ordinary Shares

LONDON and NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has...
August 07, 2019 08:00 ET | Source: MeiraGTx

MeiraGTx Reports Second Quarter 2019 Financial Results and Provides Corporate Update

LONDON and NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results...
May 14, 2019 08:00 ET | Source: MeiraGTx

MeiraGTx Reports First Quarter 2019 Financial Results and Provides Corporate Update

• Positive 6-month results from Phase 1/2 clinical trial of AAV-RPE65 • Enrollment completed in the Phase 1/2 clinical trial investigating AAV-CNGB3 gene therapy for the treatment of achromatopsia ...
May 14, 2019 07:30 ET | Source: MeiraGTx

MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiency

AAV-RPE65 met the primary endpoint of safety and tolerability Statistically significant improvement demonstrated in vision-guided mobility and visual function in treated eyes compared to untreated...
May 10, 2019 08:30 ET | Source: MeiraGTx

MeiraGTx Appoints Nicole Seligman to Board of Directors

LONDON and NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of...
May 06, 2019 16:30 ET | Source: MeiraGTx

MeiraGTx to Present at Bank of America Merrill Lynch Healthcare Conference

LONDON and NEW YORK, May 06, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes,...
April 25, 2019 16:30 ET | Source: MeiraGTx

MeiraGTx Announces Upcoming Presentation on Achromatopsia Gene Therapy Candidate AAV-CNGA3 at ARVO 2019

LONDON and NEW YORK, April 25, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced a pre-clinical poster on...